Chris Aiken, MD

Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.

Race and Psychiatry

May 9, 2022

Kali Cyrus MD, MPH, Chris Aiken, MD, and Kellie Newsome, PMHNP

To start a conversation about race, you need to know the lingo. We interview psychiatrist Kali Cyrus on internalized racism, microaggressions, implicit bias, and more.

Prescribing Psychotropics: From Drug Interactions to Pharmacogenetics (2022)

PDF/eBook with CME Post-Test Access

January 1, 2022

Chris Aiken, MD, Joshua Feder, MD, and Daniel Carlat, MD

Dr. Aiken, Dr. Feder, and Dr. Carlat have no relevant financial relationship(s) with ineligible companies to disclose.

This page has links and instructions for taking the 10 CME post-test for Prescribing Psychotropics (2022) and downloading your PDF and eBook copies.

In Brief: A 16-Hour Ritalin

October 3, 2019

Chris Aiken, MD

Adhansia XR is a new extended-release methylphenidate. Its distinguishing feature is its 16-hour duration.

A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness

July 3, 2019

Talia Puzantian, Chris Aiken, MD, and Chris Aiken

Talia Puzantian, PharmD, BCPP Chris Aiken, MD. Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Solriamfetol (Sunosi) was just approved for excessive daytime sleepiness in narcolepsy and sleep apnea, but it may have important psychiatric effects as well.

Brexanolone (Zulresso) for Postpartum Depression

July 3, 2019

Talia Puzantian, Chris Aiken, MD, and Chris Aiken

Talia Puzantian, PharmD, BCPP Chris Aiken, MD Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Every week of depression takes a toll on infant development, so this rapid-acting treatment fills a unique need. Here we review the clinical data and the pragmatics of getting patients connected with the therapy.